Endurant Capital Management’s Haemonetics HAE Stock Holding History

Endurant Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-73,914	Closed	-$3.92M	–	73
2021 Q4	$3.92M	Buy	+73,914	New	+$4.5M	0.95%	29
2021 Q3	–	Sell	-117,904	Closed	-$7.86M	–	58
2021 Q2	$7.86M	Buy	117,904 +102,765	+679%	+$7.27M	2.16%	14
2021 Q1	$1.68M	Buy	+15,139	New	+$1.87M	0.44%	51
2020 Q4	–	Sell	-41,607	Closed	-$3.63M	–	63
2020 Q3	$3.63M	Buy	41,607 +12,670	+44%	+$1.11M	1.07%	33
2020 Q2	$2.59M	Buy	+28,937	New	+$2.92M	0.14%	34
2019 Q4	–	Sell	-32,594	Closed	-$4.11M	–	60
2019 Q3	$4.11M	Buy	+32,594	New	+$4.14M	1.48%	20
2019 Q2	–	Sell	-6,691	Closed	-$585K	–	63
2019 Q1	$585K	Buy	+6,691	New	+$608K	0.23%	59

Other funds holding HAE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

LCOV

London Company of Virginia Richmond, Virginia $16.2B AUM 17.5% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Endurant Capital Management's HAE Position: Q1 2022 in Review

Endurant Capital Management sold out of Haemonetics (HAE) in Q1 2022, closing a stake of 73,914 shares — an estimated $3.92M sold.

Endurant Capital Management first reported a position in HAE in Q1 2019 and held it in 7 quarters. The position peaked at $7.86M in Q2 2021. 242 funds tracked by Wall St. Rank hold HAE as of Q1 2022.

Endurant Capital Management reported no remaining Haemonetics position as of Q1 2022 after selling out during the quarter.
Endurant Capital Management sold 73,914 Haemonetics shares in Q1 2022, an estimated $3.92M.
Endurant Capital Management first reported a position in Haemonetics in Q1 2019 and held it in 7 quarters.
Endurant Capital Management's Haemonetics position peaked at $7.86M in Q2 2021.
242 funds tracked by Wall St. Rank held Haemonetics as of Q1 2022.

Based on Endurant Capital Management's 13F filing for Q1 2022, filed 16 May 2022.